Trinity Capital committed $25 million in growth capital to Neuros Medical, a bioelectric technology company. The growth capital will enable Neuros Medical to augment a recent equity raised and further scale operations to assist with its commercial launch.
“We are proud to partner with Neuros Medical on their journey to improve the lives of those suffering from chronic post-amputation pain, and we look forward to working with their team to support their continued growth,” Rob Lake, senior managing director of life sciences at Trinity Capital, said.
“We appreciate the conviction Trinity has in the Neuros mission and our ability to scale commercialization, delivering this life-changing therapy to a large, underserved amputee population in desperate need of pain relief,” David Veino, president and CEO of Neuros Medical said.
